Efficacy and safety of third-line treatment with mesylate apatinib in patients with advanced non-small cell lung cancer

doi:10.12092/j.issn.1009-2501.2019.05.014

Abstract

Abstract:

AIM: To investigate and explore the efficacy and safety of third line treatment of mesylate apatinib in patients with advanced non-small cell lung cancer. METHODS: Designed as a retrospective study, a total of 96 patients with advanced non-small cell lung cancer from March 2015 to June 2018 were included in this study, and the clinical data and clinical outcomes were retrospectively analyzed. The 96 patients with advanced non-small cell lung cancer were treated with mesylate apatinib until the disease progress. The clinical efficacy and changes of MMP-9, VEGF and CEA were observed after two cycles treatment. The objective remission rates (ORR), disease control rates (DCR), progression-free survival (PFS) and overall survival (OS) were evaluated and safety data were recorded. RESULTS:All of the 96 patients were available for efficacy evaluation, among them, complete remission (CR) 0 cases, partial remission (PR) 16 cases, stable disease (SD) 54 cases and progression disease (PD) 26 cases. The objective remission rate (ORR) was 16.67%, and the disease control rate (DCR) was 72.92%. There were significant differences in MMP-9, VEGF and CEA between before treatment group and after treatment group (P<0.05). The median progression-free survival (mPFS) was 4.65 months. The median overall survival (mOS) was 8.90 months. In terms of safety analysis, grade 3 and above adverse reactions with high incidence were hypertension (13.54%), hand-foot syndrome (9.75%), proteinuria (7.29%), hemoptysis (7.29%), fatigue (6.25%) and hypertriglyceridemia (4.17%). CONCLUSION:Mesylate apatinib is effective and safe in the treatment of advanced non-small cell lung cancer.

Key words: non-small cell lung cancer, mesylate apatinib, efficacy, safety

CLC Number:

R734.2

WANG Haili, GONG Tianxiao, ZHOU Shixia, MEI Jiazhuan, ZHANG Zhongmian. Efficacy and safety of third-line treatment with mesylate apatinib in patients with advanced non-small cell lung cancer[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(5): 567-572.

References

［1］Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015［J］. CA Cancer J Clin, 2016, 66(2):115-132.
［2］王海霞, 刘兴安, 侯继院, 等. KDR基因遗传变异对贝伐珠单抗一线治疗晚期非小细胞肺癌患者临床疗效的影响［J］. 中国临床药理学与治疗学, 2018, 23(7): 802-808.
［3］宋勇, 高健伟. 精准医学时代的晚期非小细胞肺癌内科治疗进展［J］. 医学研究生学报, 2017, 30(11): 1121-1127.
［4］Yang Z, Tam KY. Combination strategies using EGFR-TKI in NSCLC therapy: learning from the gap between pre-clinical results and clinical outcomes［J］. Int J Biol Sci, 2018, 14(2): 204-216.
［5］贺利平, 陈毅斐, 杨炯. 前列腺素合成酶D2对非小细胞肺癌的作用及机制探讨［J］. 中华医学杂志, 2017, 97(38): 3022-3027.
［6］Toffalorio F, Santarpia M, Radice D, et al. 5'-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lung cancer［J］. Oncotarget, 2018, 9(23): 16437-16450.
［7］Zhou C, Wu YL, Chen G, et al. BEYOND: a randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer［J］. J Clin Oncol, 2015, 33(19): 2197-2204.
［8］Gridelli C, Baas P, Barlesi F, et al. Second-line treatment options in non-small-cell lung cancer: report from an international experts panel meeting of the italian association of thoracic oncology［J］. Clin Lung Cancer, 2018, 19(4): 301-314.
［9］Han B, Li K, Wang Q, et al. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 phase 3 randomized clinical trial［J］. JAMA Oncol, 2018, 4(11): 1569-1575.
［10］Li J, Qin S, Xu J, et al. Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction［J］. J Clin Oncol, 2016, 34(13): 1448-1454.
［11］李萍, 马薇, 周荣. 非小细胞肺癌靶向治疗药物的研究进展［J］. 药学与临床研究, 2017, 25(4): 130-136.
［12］陈玲娟, 伍钢, 董晓荣. 阿帕替尼二线及二线以上治疗晚期肺癌26例［J］. 医药导报, 2018, 37(5): 551-554.
［13］Shu T, Haitian Q, Chengying X, et al. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo［J］. Cancer Sci, 2011, 102(7): 1374-1380.
［14］Aguiar-Bujanda D, Duenas-Comino A, Saura-Grau S, et al. Neutrophil to lymphocyte ratio as a prognostic factor in european patients with epidermal growth factor receptor-mutant non-small cell lung cancer treated with tyrosine kinase inhibitors［J］. Oncol Res Treat, 2018, 41(12): 755-761.
［15］Fang S, Zhang M, Wei G, et al. Apatinib as a third- or further- line treatment in patients with advanced NSCLC harboring wild-type EGFR［J］. Oncotarget, 2018, 9(6): 7175-7181.
［16］Zhang D, Zhang C, Huang J, et al. Clinical investigation of the efficacy and toxicity of apatinib (YN968D1) in stage III/IV non-small cell lung cancer after second-line chemotherapy treatment: A retrospective study［J］. Thorac Cancer, 2018, 9(12): 1754-1762.
［17］Wu D, Liang L, Nie L, et al. Efficacy, safety and predictive indicators of apatinib after multilines treatment in advanced nonsquamous nonsmall cell lung cancer: Apatinib treatment in nonsquamous NSCLC［J］. Asia Pac J Clin Oncol, 2018, 14(6): 446-452.
［18］Li T, Wang SB, Lei KJ, et al. Significant response of low-dose apatinib monotherapy in brain metastases of triple-negative breast cancer: A case report［J］. Medicine (Baltimore), 2019, 98(4): e14182.

[1]	XU Yiqi, WU Qian, LIU Shu, LIU Fan, XING Chunyan, LI Qin, HE Junjun, HE Chunling, ZHAO Yongli, GAO Jialin. Clinical efficacy and anti-inflammation/anti-fibrosis effect of tripterygium glycosides in the treatment of diabetic nephropathy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1034-1042.
[2]	XIAO Yue, LI Tangfei, XUE Qianfu. Analysis of the efficacy and safety of Peg-IFN-α in the treatment of essential thrombocythemia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1049-1055.
[3]	JIA Boying, ZHOU Shuang, WAN Liyan, ZHOU Ying, CUI Yimin. Drug-induced dysphagia risk in elder people——A pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) database [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1109-1120.
[4]	LIU Min, KONG Xiang, ZHANG Ye, GU Yifei, XIANG Xuemei, HUANG Kai. Safety analysis on bioequivalence studies of orally inhaled drug products in healthy Chinese subjects#br# [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1131-1138.
[5]	HUANG Xiaoming, DU Ye, LIN Shaoming, SHEN Guanle. Exploratory study of the influence of respiratory microbiology on the efficacy of PD-1 inhibitors monotherapy for patients with advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 66-74.
[6]	ZHANG Kexin, JIA Wenjing, CUI Jiawen, AO Luyao, ZHOU Fang, WANG Guangji, LIU Jiali. Advances in the research and clinical application of the third generation EGFR TKIs in the treatment of non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1016-1030.
[7]	LIANG Meifang, CHEN Qingzhuang, YANG Peiqun, WANG Yong. Efficacy and safety of generic and branded atorvastatin in patients with ischemic stroke/transient ischemic attack: A real-world study [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 785-792.
[8]	YANG Mengjiao, YUAN Hao, ZHENG Ya, WANG Yuping, GUO Qinghong. Advances in the treatment of potassium-competitive acid blockers in reflux esophagitis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(10): 1190-1196.
[9]	BAO Jing, CHEN Xiaowen, XIA Liang, ZHAO Yuchen, XIA Ruixiang, XIA Hailong. Clinical efficacy and safety of ixazomib in the treatment of multiple myeloma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 782-786.
[10]	HUANG Yiting, SHEN Aizong. Clinical research progress of afatinib therapy for lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 474-480.
[11]	LI Jing, Ma Lijuan, YUAN Yuan, WANG Jie, YU Changzhi, ZHAO Jun. Relationship between gene polymorphism of inhaled glucocorticosteroids budesonide and efficacy in asthma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(11): 1250-1258.
[12]	PEI Qinghua, SUN Jianli. Research progress of Osimertinib acquired resistance [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(1): 105-112.
[13]	LIN Rongfang, ZHENG Weiwei, LIU Yiwei, LIN Cuihong, WANG Changlian, HUANG Pinfang. Correlation of infliximab related genetic polymorphism, serum trough concentration and efficacy in patients with Crohn's disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 1000-1006.
[14]	WEI Weitian, CHEN Sheng, WANG Liang, ZENG Jian. Breviscapine induced the apoptosis of non-small cell lung cancer A549 cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(6): 618-624.
[15]	PAN Luping, SHI Wujie, SHEN Zhipeng. Efficacy and safety of etoposide combined with carboplatin in children with recurrent medulloblastoma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(2): 189-195.